Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + oxaliplatin + lenvatinib + toripalimab + hepatic arterial infusion chemotherapy
- Development stage
- Phase 3
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Hepatic Arterial Infusion
01
Overview
This combination therapy is an investigational regimen developed by Sun Yat-sen University for the treatment of advanced or unresectable intrahepatic cholangiocarcinoma (ICC). The regimen integrates systemic chemotherapy (GemOx: gemcitabine and oxaliplatin), the multikinase inhibitor lenvatinib, and the anti-PD-1 monoclonal antibody toripalimab, supplemented by Hepatic Arterial Infusion Chemotherapy (HAIC) using oxaliplatin. This multimodal approach aims to leverage the cytotoxic effects of chemotherapy, the anti-angiogenic and anti-proliferative properties of lenvatinib, and the immune-restoring capabilities of toripalimab. The addition of HAIC provides a localized, high-concentration delivery of chemotherapy directly to the liver via the hepatic artery, potentially improving local tumor control and overall survival in patients with advanced ICC.
- Other names
- HAIC + GemOx + Lenvatinib + ToripalimabHAIC-GemOx-Lenvatinib-Toripalimab
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on gemcitabine + oxaliplatin + lenvatinib + toripalimab + hepatic arterial infusion chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + oxaliplatin + lenvatinib + toripalimab + hepatic arterial infusion chemotherapy.